On August 21, 2018, GB Sciences (OTC:GBLX) and the LSU AgCenter began operation of medical cannabis in an environmentally controlled grow pod.
The first plants were developed through tissue culture propagation to ensure genetic consistency. Later, once at full capacity the facility will have plants at staggering stages of growth which would enable a continuous harvesting cycle for Louisiana’s therapeutic cannabis program. The cannabis is expected to be available in November.
“The research…will be cutting edge in the field of cannabis studies, and our partnership with GB will allow us…to look at the plant like it’s never been looked at before,” said LSU AgCenter Research Associate Professor Ted Gauthier.
“We’re excited…because their scientists are doing the same things with…sweet potatoes, rice, and sugar cane,” said John Davis, President of GB Sciences Louisiana. “And we’re excited about what can come from the partnership: inventions, new strains, and a genetics databank.”
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on developing cultivation and production methods; as well as biopharmaceutical R&D. Its goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions.
Source: GB press release